Trial Profile
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Prednisolone (Primary) ; Vincristine (Primary) ; Bleomycin; Bleomycin; Methylprednisolone
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results (n=302) from a prespecified longitudinal patient-reported outcomes sub study assessing impact on health-related quality of life (HRQoL) with the addition of BV presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 01 Dec 2023 Planned End Date changed from 31 Dec 2029 to 22 Sep 2024.